|
Investigation of the Cytotoxic Effects of Sertraline on Pancreatic Cancer and Non-Cancerous Kidney Cells
|
Sogol Fereydouni Balangani   , Atefeh Hassanli , Rahim Ahmadi , Nooshin Amini * |
| Member Global Research, Education, and Event Network (GREEN), Iran & Member Global Research, Education, and Event Network (GREEN), Iran , amini.n.2486@gmail.com |
|
|
Abstract: (12 Views) |
Background and Aim: Pancreatic cancer is one of the deadliest cancers, characterized by poor prognosis and high drug resistance. Drug repurposing offers a rapid and cost-effective strategy for developing novel therapeutic approaches. This study aimed to investigate the cytotoxic effects of sertraline on pancreatic cancer cells (PANC-1) and non-cancerous kidney cells (HEK293).
Materials and Methods: PANC-1 and HEK293 cells were cultured in vitro and treated with serial concentrations of sertraline in the range of approximately 1.953125 to 500 µg/mL. Cell viability was assessed using the MTT assay. Data were analyzed using one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test. The IC₅₀ value was calculated from dose-response curves using GraphPad Prism software.
Results: Sertraline caused a dose-dependent significant reduction in PANC-1 cell viability (P<0.001), whereas HEK293 cells were less sensitive, indicating relative selectivity of the drug for cancer cells. The IC₅₀ for PANC-1 cells was approximately 15.7 µg/mL, demonstrating a considerable inhibitory effect of sertraline on cancer cell growth.
Conclusion: Sertraline may serve as a promising repurposed drug for pancreatic cancer treatment. However, further preclinical studies and clinical trials are required to fully evaluate its safety and efficacy. These findings provide a foundation for developing more effective and less toxic therapeutic strategies for patients with pancreatic cancer. |
|
| Keywords: Sertraline, PANC-1, HEK293, Cytotoxic, Pancreatic Cancer |
|
|
|
Type of Study: Research |
Subject:
General
Received: 2025/09/22 | Revised: 2025/11/12 | Accepted: 2025/11/12
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
_-_Copy.png)
.png){kind=logo}
